Department of Error (DOI:10.1016/S0140-6736(06)69394-X);Compliance with osteoporosis therapy is the weakest link

Lancet

Volumn 368, Issue 9540, 2006, Pages 973-974

  Compston, Juliet E ^a,b   Seeman, Ego ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PLACEBO; RISEDRONIC ACID;

ARTICLE; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MORBIDITY; MORTALITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 33748455223     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60407-3     Document Type: Erratum

References (12)

1. Cummings S., and Melton L. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1777
2. Caro J., Ishak K., Huybrechts K., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
3. Huybrechts K., Ishak K., and Caro J. Assessment of compliance with osteoporosis and its consequences in a managed care population. Bone 38 (2006) 922-928
4. Siris E., Harris S., Rosen C., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
5. McCombs J., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
6. Anonymous. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 303 (1980) 1038-1041
7. Horwitz R., Viscoli C., Berkman L., et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 336 (1990) 542-545
8. Guilera M., Fuentes M., Grifols M., Ferrer J., and Badia X. Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study. Osteoporos Int 17 (2005) 1-8
9. Solomon D., Avorn J., Katz J., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
10. Clowes J., Peel N., and Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89 (2004) 1117-1123
11. Cramer J., Amonkar M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460
12. Cooper A., Drake J., and Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs once-weekly alendronate. Int J Clin Prac 60 (2006) 896-905